Superworth

Aytu Biopharma EPS AYTU

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Mar 31, 2026
n/m
a quarter missing
Latest quarter, Q3 FY26
−$0.53
−352% on a year earlier
Fiscal year 2023
−$4.96

Aytu Biopharma's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY26, it was −$0.53, down 352% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2023−$4.96n/a
FY2022−$75.34n/a
FY2021−$65.80n/a
FY2020−$102.20n/a
FY2019−$846.00n/a
FY2018−$11494.00n/a
FY2017−$217680.00n/a
FY2016−$1152560.00n/a
FY2015n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26−$0.53−352%n/a
Q2 FY26−$1.05n/an/a
Q1 FY26−$0.08n/an/a
Q3 FY25$0.21n/an/a
Q2 FY25−$0.26n/an/a
Q1 FY25−$0.15n/an/a
Q3 FY24−$0.52n/a−$2.64
Q2 FY24−$0.04n/a−$4.05
Q1 FY24−$1.48n/a−$6.16
Q4 FY23−$0.60n/a−$4.96
Q3 FY23−$1.93n/a−$13.30
Q2 FY23−$2.15n/a−$47.27

Against its peers

Companies in Drug Manufacturers - General nearest Aytu Biopharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
AYTUAytu Biopharman/m
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Aytu Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.